APA

Ahmed K., Kren B. T., Abedin M. J., Vogel R. I., Shaughnessy D. P., Nacusi L., Korman V. L., Li Y., Dehm S. M., Zimmerman C. L., Niehans G. A., Unger G. M. & Trembley J. H. (20180319). CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. : Oncotarget.

Chicago

Ahmed Khalil, Kren Betsy T, Abedin Md Joynal, Vogel Rachel I, Shaughnessy Daniel P, Nacusi Lucas, Korman Vicci L, Li Yingming, Dehm Scott M, Zimmerman Cheryl L, Niehans Gloria A, Unger Gretchen M and Trembley Janeen H. 20180319. CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. : Oncotarget.

Harvard

Ahmed K., Kren B. T., Abedin M. J., Vogel R. I., Shaughnessy D. P., Nacusi L., Korman V. L., Li Y., Dehm S. M., Zimmerman C. L., Niehans G. A., Unger G. M. and Trembley J. H. (20180319). CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. : Oncotarget.

MLA

Ahmed Khalil, Kren Betsy T, Abedin Md Joynal, Vogel Rachel I, Shaughnessy Daniel P, Nacusi Lucas, Korman Vicci L, Li Yingming, Dehm Scott M, Zimmerman Cheryl L, Niehans Gloria A, Unger Gretchen M and Trembley Janeen H. CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. : Oncotarget. 20180319.